INSULIN Act of 2026
The source supplies the latest action, but no lifecycle stage.
Latest action (2 Sep 2026): Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What this bill does
The INSULIN Act of 2026 (H.R. 10227) would set new limits on what health plans can charge patients for insulin and create supporting programs to help people access it. Beginning with plan years starting on or after January 1, 2028, most group and individual health insurance plans would be required to cover at least one form of each major type of insulin without applying a deductible, and to cap patient cost-sharing at $35 per 30-day supply or, if lower, 25 percent of the insulin's negotiated net price. Plans generally could not impose prior authorization or similar restrictions on these insulin products except for limited safety reasons. Catastrophic health plans would also have to cover selected insulin before patients meet the plan's cost-sharing limit.
The bill primarily affects people with private or employer-sponsored health insurance who use insulin, capping their out-of-pocket costs. It also directs the Government Accountability Office to study the characteristics of uninsured insulin users and requires the Department of Health and Human Services to fund a grant-supported resource center and 24/7 hotline to help uninsured individuals find insulin assistance programs, with $2 million authorized annually from fiscal years 2027–2032. Additionally, it allows the FDA to expedite review of biosimilar insulin or other biological products in cases of inadequate market competition.
The bill was introduced on September 2, 2026, by Rep. Diana DeGette with bipartisan cosponsors, and referred to the House Committees on Energy and Commerce, Ways and Means, and Education and Workforce. It has not yet been voted on in committee or by the full House.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Timeline
2 Sep 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Common questions
- What does H.R. 10227 do?
- The INSULIN Act of 2026 (H.R. 10227) would set new limits on what health plans can charge patients for insulin and create supporting programs to help people access it. Beginning with plan years starting on or after January 1, 2028, most group and individual health insurance plans would be required to cover at least one form of each major type of insulin without applying a deductible, and to cap patient cost-sharing at $35 per 30-day supply or, if lower, 25 percent of the insulin's negotiated net price. Plans generally could not impose prior authorization or similar restrictions on these insulin products except for limited safety reasons. Catastrophic health plans would also have to cover selected insulin before patients meet the plan's cost-sharing limit. The bill primarily affects people with private or employer-sponsored health insurance who use insulin, capping their out-of-pocket costs. It also directs the Government Accountability Office to study the characteristics of uninsured insulin users and requires the Department of Health and Human Services to fund a grant-supported resource center and 24/7 hotline to help uninsured individuals find insulin assistance programs, with $2 million authorized annually from fiscal years 2027–2032. Additionally, it allows the FDA to expedite review of biosimilar insulin or other biological products in cases of inadequate market competition. The bill was introduced on September 2, 2026, by Rep. Diana DeGette with bipartisan cosponsors, and referred to the House Committees on Energy and Commerce, Ways and Means, and Education and Workforce. It has not yet been voted on in committee or by the full House.
- Has H.R. 10227 become law?
- The source does not supply a confirmed lifecycle stage for H.R. 10227. Check the latest action and official source below.
- Who sponsored H.R. 10227?
- H.R. 10227 was sponsored by Rep. DeGette, Diana [D-CO-1] (D-CO), with 19 cosponsors.
- What's the latest action on H.R. 10227?
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (2 Sep 2026).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Lower Premiums, Faster Payments Act
Access to Medical Supplies Act
More bills from Rep. DeGette, Diana [D-CO-1]
DeOndra Dixon INCLUDE Project Act of 2025
DOGE POUND Act of 2025
Tobacco to 21 Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.